← Oncology Approval Tracker

FDA DECISION ·

Enhertu → THP

fam-trastuzumab deruxtecan-nxki followed by a taxane, trastuzumab and pertuzumab · Daiichi Sankyo

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Neoadjuvant treatment for adults with stage II or III HER2-positive breast cancer, defined as IHC 3+ or ISH-positive on an FDA-authorized test.

LAMPGEN ANALYSIS

Why it matters

This moves an ADC into treatment before surgery. Pathologic complete response at surgery addresses a different question from long-term recurrence and survival.

What research teams should watch

Capture pretreatment HER2 and stage, the transition to THP and surgical pathology. Keep the neoadjuvant protocol distinct from the residual-disease adjuvant indication.

PRIMARY RECORDS

Sources